Clinical Trial Update: Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CHOP plus lenalidomide as first-line therapy in angioimmunoblastic T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: T-cell Lymphoma | Phase 2 | Status: COMPLETED